{
    "nct_id": "NCT04245540",
    "official_title": "A Single Arm, Open-label Pilot Trial Examining the Effects of Pau d' Arco on Primary Dysmenorrhea in Reproductive Age Women",
    "inclusion_criteria": "* Biologically female\n* Ages 18-45\n* Presence of primary dysmenorrhea\n* Has a 'smart' phone and is willing to download and use an electronic application for use during the study.\n* Willing to take a non-hormonal form of birth control throughout the trial period (abstinence, condom, diaphragm, or copper IUD (ParaGard))\n* Lives in the Portland area\n* Able to speak, read and write English\n* Has reliable transportation to clinic\n* Willing to have four fasting blood draws taken\n* Wiling to collect menstrual fluid in a Diva© cup on the first day of menstruation and ability to deliver it to the clinic on the same day\n* Ability to receive and complete electronic VAS scales\n* Pain scale rating of 6 or higher on the VAS scale\n* Monthly pain that correlates with menstruation\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years\nMust have maximum age of 45 Years",
    "exclusion_criteria": "* Presence of secondary dysmenorrhea\n* General health measures outside of normal range:\n\n  * Blood pressure readings obtained at the Screening Visit reveal hypotension (≤90/60 mmHg) or hypertension (≥140/90 mmHg).\n  * Aspartate aminotransferase (AST) < 8 U/L or > 48 U/L at the Screening Visit.\n  * Alanine aminotransferase (AST) < 7 U/L or > 55 U/L at the Screening Visit.\n  * Estimated glomerular filtration rate (eGFR) < 90 ml/min/1.73m2 at the Screening Visit.\n  * An INR value > 1.1 at the Screening Visit.\n  * A red blood cell count < 3.90 million cells/mcL or > 5.03 million cells/mcL.\n  * A hemoglobin value of < 12 g/dL (120 g/L) or > 15.5 g/dL (155 g/L).\n  * A hematocrit value of < 34.9% or > 44.5%.\n  * A white blood cell count < 3.5 billion cells/L (3,500 cells/mcL) or > 10.5 billion cells/L (10,500 cells/mcL)\n  * A platelet count < 150 billion/L (150,000/mcL) or > 450 billion/L (450,000 mcL).\n* Women who are nursing, pregnant, or planning pregnancy in the next four months\n* Difficulty swallowing or aversion to capsules, tablets, or pills\n* Currently taking, and unwilling to discontinue, NSAIDs (Aspirin, Ibuprofen)\n* Currently taking dietary supplements with any of the following ingredients in amounts over 250 mg/day: cinnamon, garlic, ginger, turmeric, and/or curcumin\n* Consumption of >1 alcoholic drink per day, during the study period\n* Currently taking any anticoagulation medications (Warfarin/Coumadin)\n* Currently taking, or have taken in the past two months, hormonal forms of birth control\n* Unwillingness, or inability, to take a monthly pregnancy test during the timeline of the study (3 pregnancy tests)\n* Past or present medical history of any of the following:\n\n  * Blood clotting disorders (von Willebrand disease, Hemophilia A, Hemophilia B, etc.)\n  * Liver disease (cirrhosis, hepatitis, liver failure, jaundice, liver cancer, etc.)\n  * Kidney disease (chronic kidney disease, polycystic kidney disease, etc.)\n  * Cardiac disease (hypertension, heart failure, cardiomyopathy, etc.)\n  * Anemia (iron deficiency, sickle cell, aplastic, etc.)\n  * Inflammatory bowel disease\n  * Irritable bowel syndrome\n  * Endometriosis\n  * Obstructive endometrial polyps\n  * Chronic pelvic inflammatory disease\n  * Polycystic Ovarian Syndrome\n  * Adenomyosis\n  * Intrauterine or pelvic adhesions\n  * Congenital obstructive mullerian malformations\n  * Cervical stenosis\n  * Use of an intrauterine contraceptive device that causes pain\n  * Pelvic congestion syndrome\n  * Reproductive cancer (uterine cancer, ovarian cancer, endometrial cancer, etc.)\n  * Ovarian cysts\n  * Fibroids\n  * Uteropelvic junction obstruction",
    "miscellaneous_criteria": ""
}